Pink SheetThe US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner
ScripAssertio Holdings, Inc. is banking on a recently approved oncology drug from Spectrum Pharmaceuticals Inc. in its move to acquire that company for nearly a quarter of $1bn, while viewing it as a wa
ScripA likely approval for a biosimilar to Eli Lilly and Company ’s Forsteo (teriparatide) in the European Union will add a ‘significant’ but ‘not a massive’ product to the portfolio of Biolexis, the prod